Trial Profile
Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 2647544 (Primary) ; Simvastatin
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 10 Oct 2016 Results of this and other trial (NCT01702467) published in the International Journal of Clinical Pharmacology and Therapeutics
- 05 Jun 2014 Trial status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Nov 2013 Planned number of patients changed from 70 to 48 as reported by ClinicalTrials.gov.